Page 39 - CIBERES2016-ENG

Most relevant scientific articles
• McEvoy R.D., Antic N.A., Heeley E., Luo Y., Ou Q., Zhang X. et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. New England Journal of Medicine. 2016;375(10):919-931.
• Lee C.-H., Barbe F. Adaptive servoventilation for central sleep apnoea in heart failure: a broken dream. The Lancet Respiratory Medicine. 2016;4(11):846-847.
• Campos-Rodriguez F., Queipo-Corona C., Carmona-Berna C., Jurado-Gamez B., Cordero-Guevara J., Reyes-Nunez N. et al. Continuous positive airway pressure improves quality of life in women with obstructive sleep apnea a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2016;194(10):1286-1294.
• Martinez-Ceron E., Barquiel B., Bezos A.-M., Casitas R., Galera R., Garcia-Benito C. et. al. Effect of continuous positive airway pressure on glycemic control in patients with obstructive sleep apnea and type 2 diabetes a randomized clinical trial. American Journal of Respiratory and Critical Care Medicine. 2016;194(4):476-485.
• Vicente E., Marin J.M., Carrizo S.J., Osuna C.S., Gonzalez R., Marin-Oto M. et. al. Upper airway and systemic inflammation in obstructive sleep apnoea. European Respiratory Journal. 2016;48(4):1108- 1117.
Highlights
The G35 (CIBERES) led by Ferran Barbé focuses his activity on the study of Sleep Apnea Syndrome (SAHS). During 2016 I publish 51 original publications. In addition, it received funding in competitive calls for the development of 22 new research projects and 18 clinical trials. The projects develop the objectives of
the CIBERES 2016-18 Sleep Line, being: i) To characterize different SAHS phenotypes and to improve the management of the disease. Ii) To evaluate the impact of SAHS and its treatment in the development of comorbidities with high mortality and high social impact. He has obtained recognition of the Caixaimpulse program for the development of the first technology for application of personalized medicine in the
SAHS, which evaluates the response to CPAP treatment in patients with resistant hypertension and SAHS. The papers have been published in the first journal of the category of Cardiac & Cardiovascular Systems (Journal of the American College of Cardiology (JACC)) and recognized with Best Publication of the SES 2016. Moreover, it has led nationally, The most relevant international study so far for evaluating the impact of CPAP treatment on secondary prevention of cardiovascular disease. The results were published in
New England Jounal or Medicine. In addition, in 2017, the first global study, conducted by Group 35, was completed to determine the prevalence of sleep disorders in COPD. Group 35 continues its involvement in the development of several simplified device transfer contracts for the diagnosis of SAHS. Finally, to highlight different acknowledgments received such as the Young Researcher Award AstraZeneca 2016, Young Lesson SEPAR 2015 and ATS Young Researcher 2016, as well as participation in national meetings and more prestigious internationals through conferences by invitation.
RES
research groups 39